Biosense Webster unveils new version of CARTO 3 Electro-Anatomical Mapping System

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-05-11 10:42 GMT   |   Update On 2024-05-11 12:11 GMT

Irvine: Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, has announced the launch of CARTO 3 System Version 8, the latest version of the company’s three-dimension (3D) heart mapping system used in cardiac ablation procedures. The software features new modules including the CARTO ELEVATE Module and CARTOSOUND FAM Module, designed for efficiency, reproducibility, and accuracy for electrophysiologists performing catheter ablation procedures to treat patients with atrial fibrillation (AFib) and other arrhythmias.

Advertisement

“We are pleased to announce this new version of our CARTO 3 System, which reflects our continued focus on harnessing the latest science and technology to advance tools for electrophysiologists to treat cardiac arrhythmias,” said Jasmina Brooks, President, Biosense Webster, Inc. “The CARTO 3 System has been the cornerstone of catheter ablation procedures for more than a decade, helping electrophysiologists make treatment decisions. This new version advances the CARTO 3 mapping and ablation experience through enhanced signal analysis, improved substrate characterization, and utilization of ultrasound technology.”

New optional CARTO 3 System Version 8 modules include:

CARTOSOUND FAM: the first use of an artificial intelligence algorithm, cleared by the FDA in intracardiac ultrasound for Biosense Webster. The algorithm enables automatic generation of the left atrial anatomy before inserting the catheter to the left atrium, saving time while also providing a highly accurate map.

CARTO ELEVATE: incorporates several new features designed to meet electrophysiologists’ needs:

  • Multipolar with the OPTRELL Mapping Catheter for localized unipolar signals to significantly reduce far field potentials and provide a more accurate activation map;
  • Complex signals identification for efficient and reproducible identification of critical areas of interest when diagnosing the arrhythmia;
  • Pattern acquisition to automatically track arrhythmia burden pre- and post-ablation, enabling a more informed decision of the relevant premature activation map; and
  • Enhanced CONFIDENSE Module to create optimized maps with higher overall Smart Index scores, ensuring maps are continuously improved.

“CARTO 3 System Version 8 incorporates a novel component, the CARTOSOUND FAM Module, which, for the first time, utilizes artificial intelligence to reconstruct the left atrial anatomy, streamlining the process for electrophysiologists,” said Luigi Di Biase, M.D.v, PhD, FACC, FHRS, FESC, System Director Electrophysiology at Montefiore-Einstein Health System and Professor of Medicine (Cardiology), Albert Einstein College of Medicine. “By eliminating the need for manual contouring, the new system represents a new approach to anatomy creation, improving the efficiency of the procedure workflow.”

“Accuracy and precision in mapping the heart when treating cardiac arrhythmias are critical for electrophysiologists, and therefore, our patients,” continued Dr. Di Biase. “The CARTO ELEVATE Module raises the bar for electro-anatomical mapping systems used in catheter ablation procedures. Capabilities such as Multipolar mapping make a difference for electrophysiologists in the electrophysiology lab, facilitating a reduction in far-field signal and increased focus on the electrical signals in the patient’s heart that contribute to arrhythmias.”

AFib is the most common type of cardiac arrhythmia and affects more than 8 million people in the United States and nearly 50 million people worldwide. Catheter ablation is a safe and effective procedure when drugs don’t work to help restore the heart’s incorrect electrical signals, which cause an abnormal heart rhythm.

Read also: JnJ Medtech's Biosense Webster gets nod for VARIPULSE Pulsed Field Ablation platform in Japan

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News